Jagsonpal Pharmaceuticals Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-20
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
|---|---|---|---|---|
| Sales | 59 Cr | 76 Cr | 74 Cr | 73 Cr |
| Operating expenses (approx.) | 47 Cr | 59 Cr | 55 Cr | 56 Cr |
| EBITDA | 11 Cr | 17 Cr | 19 Cr | 17 Cr |
| OPM % | 19.2% | 22.5% | 26.1% | 23.5% |
| Other income | 3 Cr | 3 Cr | 3 Cr | 3 Cr |
| Interest | 0.26 Cr | 0.25 Cr | 0.27 Cr | 0.26 Cr |
| Depreciation | 2 Cr | 2 Cr | 2 Cr | 2 Cr |
| Profit before tax | 9 Cr | 14 Cr | 17 Cr | 15 Cr |
| Tax % | 24.4% | 25.2% | 25.2% | 24.6% |
| Net profit | 7 Cr | 11 Cr | 13 Cr | 11 Cr |
| EPS (₹) | ₹0.98 | ₹1.60 | ₹1.88 | ₹1.67 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | TTM |
|---|---|---|
| Sales | 269 Cr | Sign in for TTM |
| Operating expenses (approx.) | 190 Cr | Sign in for TTM |
| EBITDA | 79 Cr | Sign in for TTM |
| OPM % | 29.4% | Sign in for TTM |
| Other income | 8 Cr | Sign in for TTM |
| Interest | 0.96 Cr | Sign in for TTM |
| Depreciation | 8 Cr | Sign in for TTM |
| Profit before tax | 70 Cr | Sign in for TTM |
| Tax % | 20.8% | Sign in for TTM |
| Net profit | 55 Cr | Sign in for TTM |
| EPS (₹) | ₹8.26 | Sign in for TTM |
| Dividend payout % | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 |
|---|---|
| Equity capital | 13 Cr |
| Reserves | 227 Cr |
| Borrowings | — |
| Other liabilities | 38 Cr |
| Total liabilities | 278 Cr |
| Fixed assets (net) | 0.61 Cr |
| CWIP | 0.0000 Cr |
| Investments | 0.0000 Cr |
| Other assets | 161 Cr |
| Total assets | 278 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 |
|---|---|
| Cash from operating activity | 55 Cr |
| Cash from investing | -45 Cr |
| Cash from financing | -12 Cr |
| Net cash flow | -2 Cr |
| Free cash flow (OCF − Capex) | 55 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2025 |
|---|---|
| ROCE % | 29.5% |
| ROE % | 23.1% |
| Debtor days | — |
| Inventory days | 302 |
| Days payable | — |
| Cash conversion cycle | 302 |
| Debt / equity | 0.00 |
| Current ratio | 6.22 |
| Net debt / EBITDA | -0.14 |
Compare with peers
Loading peers…